Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo

E Arai1, Y Nishida*,1, J Wasa1, H Urakawa1, L Zhuo2, K Kimata2, E Kozawa1, N Futamura1 and N Ishiguro1

1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan; 2Research Complex for the Medicine Frontiers, Aichi Medical University, Karimata 21, Yazaka, Nagakute, Aichi 480-1195, Japan

BACKGROUND: Hyaluronan (HA) plays crucial roles in the tumourigenicity of many types of malignant tumours. 4-Methylumbelliferone (MU) is an inhibitor of HA synthesis. Several studies have shown its inhibitory effects on malignant tumours; however, none have focused on its effects on osteosarcoma.

METHODS: We investigated the effects of MU on HA accumulation and tumourigenicity of highly metastatic murine osteosarcoma cells (LM8) that have HA-rich cell-associated matrix, and human osteosarcoma cell lines (MG-63 and HOS).

RESULTS: In vitro, MU inhibited HA retention, thereby reducing the formation of functional cell-associated matrices, and also inhibited cell proliferation, migration, and invasion. Akt phosphorylation was suppressed by MU (1.0 mm). In vivo, although MU showed only a mild inhibitory effect on the growth of the primary tumour, it markedly inhibited (75% reduction) the development of lung metastasis. Hyaluronan retention in the periphery of the primary tumour was markedly suppressed by MU.

CONCLUSION: These findings suggested that MU suppressed HA retention and cell-associated matrix formation in osteosarcoma cells, resulting in a reduction of tumourigenicity, including lung metastasis. 4-Methylumbelliferone is a promising therapeutic agent targeting both primary tumours and distant metastasis of osteosarcoma, possibly via suppression of HA retention.

British Journal of Cancer (2011) 105, 1839–1849. doi:10.1038/bjc.2011.459 www.bjcancer.com Published online 1 November 2011 © 2011 Cancer Research UK

Keywords: 4-methylumbelliferone; hyaluronan; extracellular matrix; osteosarcoma; lung metastasis

The prognosis of osteosarcoma patients has improved dramatically with the introduction of chemotherapy; however, cases with metastases or an unresectable tumour still have a poor prognosis. Moreover, survival of patients with osteosarcoma has not improved with conventional chemotherapy over the past two decades. There is, thus, an urgent need to develop novel agents that do not cause serious complications or interfere with the function, ADL, or QOL of patients with osteosarcoma.

Increased hyaluronan (HA) levels in malignant tumours have been reported in cases of gastric, colorectal, breast, glioma, lung, and ovarian cancers (Pirinen et al, 1998; Ropponen et al, 1998; Setala et al, 1999; Anttila et al, 2000; Auvinen et al, 2000). Several studies have shown that HA levels correlate with the proliferation, motility, invasion, and metastasis of malignant tumour cells (Mummert et al, 2003; Ricciardelli et al, 2007; Bharadwaj et al, 2009). This may occur partly because an increased HA-rich matrix may support invasion by providing cancer cells with a suitable microenvironment (Knudson et al, 1989), stimulate cell motility via interactions of HA with cell-surface receptors (Yang et al, 1993), or form a barrier for cancer cells against host immunocompetent cells (McBride and Bard, 1979). Moreover, increased pericellular HA levels may lead to drug resistance against anticancer agents (Suzuki et al, 2009; Toole, 2009).

In osteosarcoma, antisense inhibition of HAS2 suppressed HA retention and tumourigenicity (Nishida et al, 2005), and administration of HA oligosaccharides inhibited endogenous HA deposition via interaction with CD44, a cell-surface receptor of HA, resulting in suppression of the tumourigenicity of two osteosarcoma cell lines (Hosono et al, 2007). However, the clinical application of these modalities is difficult because of ethical issues and/or the problems associated with efficient drug delivery.

4-Methylumbelliferone (MU), a modified coumarin (7-hydroxy-4-methylcoumarin), is a cholagogue and is widely used as an oral medicine in Japan (Takeda and Abeura, 1981). It is also known to inhibit HA synthesis via glucuronidation by endogenous glucuronosyltransferase (UGT), which results in depletion of uridine diphosphate glucuronic acid (UDP-GlcUA) (Kakizaki et al, 2004). Some studies have shown the anticancer effects of MU through the inhibition of HA synthesis in vitro and in vivo with or without anticancer agents (Yoshihiara et al, 2005). However, no study has investigated the inhibitory effects of MU on osteosarcoma. Compared with epithelial malignant tumours, malignant cells of mesenchymal origin have more abundant ECM, and HA plays a crucial role in maintaining the integrity of ECM.

In this study, we hypothesised that the inhibition of HA synthesis by MU in osteosarcoma cells with an HA-rich ECM might alter the formation of ECM and the tumourigenicity of cells. We investigated the in vitro and in vivo effects of MU on highly metastatic osteosarcoma cells, LM8, that have an HA-rich ECM, in addition to the human osteosarcoma cell lines MG-63 and HOS.
MATERIALS AND METHODS

Chemicals

4-Methylumbelliferone was purchased from Wako Pure Chemicals (Osaka, Japan). Highly purified hyaluranan (Artz) was purchased from Kaken Pharmaceutical (Tokyo, Japan). Specific primers for mouse Has1 (hyaluronan synthase-1), Has2 (hyaluronan synthase-2), Has3 (hyaluronan synthase-3), CD44, Hyal1 (hyaluronidase-1), Hyal2 (hyaluronidase-2), Hyal3 (hyaluronidase-3), and glyceroldehyde-3-phosphate dehydrogenase (GAPDH) and human HAS1 (hyaluronan synthase-1), HAS2 (hyaluronan synthase-2), HAS3 (hyaluronan synthase-3), CD44, and GAPDH were custom made by Nihon Gene Research Laboratories (Sendai, Japan). Short-interfering RNAs (MISSION esiRNA) were purchased from Sigma-Aldrich (St Louis, MO, USA).

Cell culture

All experiments were conducted according to the Regulations for Animal Experiments in our institution, and the Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions in Japan. The mouse highly metastatic osteosarcoma cell line, LM8, was a kind gift from Mie University (Mie, Japan). The human osteosarcoma cell lines, MG-63 and HOS, were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were grown as monolayers. The MU stock solution for in vitro experiments was dissolved in DMSO, and the final concentration of DMSO in the medium was adjusted to 1.0%.

Observation of functional cell-associated matrix

Cell-associated pericellular matrices were observed using a particle exclusion assay (Knudson, 1993). The cells were observed and photographed with an inverted phase-contrast microscope. The functional cell-associated matrix areas of randomly selected cells were captured as digital images and analysed using Scion Image software (Scion Corporation, Frederick, MD, USA). Morphometric analyses were performed to determine the proportions of the area delineated by the cell-associated matrix area to the area delineated by the plasma membrane area. To analyse whether exogenous HA is able to cancel the MU effects, cell-associated matrix formation was determined after a 72-h co-incubation of 1.0 mM MU with or without 200 μg ml⁻¹ of exogenous HA.

Conventional and real time RT-PCR analysis

On the basis of a recent report that showed that MU downregulated HA mRNA levels in several human cell lines (Kultti et al, 2009), we determined the expression levels of Has1, Has2, Has3, and CD44 in LM8 cells after incubation with or without MU. Cells were cultured with or without 1.0 mM MU for 24 h. Total cellular RNA was isolated, and subjected to the conventional reverse transcription-PCR (RT-PCR). The RT-PCR revealed that Has2 mRNA could not be detected in LM8 cells, and cDNA was subjected to real-time RT-PCR for semiquantification of Has1, Has3, and CD44 mRNAs using a LightCycler (Roche Diagnostics, Mannheim, Germany). The relative levels of target mRNAs in a sample were expressed as relative quantification normalised against GAPDH mRNA levels. We also determined the mRNA expression of Hyal1, Hyal2, and Hyal3 in LM8 cells after 24 h of incubation with or without MU using the conventional RT-PCR. Expression levels for Bax and bcl-2 mRNA were determined using real-time RT-PCR for evaluation of apoptotic activity. Sequences of primer pairs used in this study, and expected product size are provided in Supplementary Online Material.

Immunocytochemistry for Has

The LM8 cells were seeded onto chamber slides (BD Biosciences, Mountain View, CA, USA), allowed to adhere to the bottom of the slides for 12 h, and then incubated with 0–1.0 mM MU for 24 h. Then, cultured cells were subjected to Has1 and Has3 immunocytochemistry. Polyclonal antibodies against Has1 and Has3 were raised in rabbits by subcutaneous injection of the following synthetic peptides: VRRLCRRRSGGTRVGV, corresponding to amino acids 568–582 of Has1, and CGKKPEQYSLFAE, corresponding to amino acids 541–555 of Has3, which had been coupled to keyhole limpet haemacytin. The specificity of the purified antibodies has been confirmed (Tominaga et al, 2001).

Cell viability assay

Cultured cells were exposed to 10% FBS medium with 1% DMSO containing 0–1.0 mM MU with or without 200 μg ml⁻¹ of exogenous HA. A previous report showed that the molecular weight of HA synthesised by Has1 or Has2 was 2 × 10⁵ to ~2 × 10⁶ Da, and that of Has3 was 1 × 10⁵ to 1 × 10⁶ Da (Itano et al, 1999). Considering that MU inhibits HA synthesised by Has1, we used ~8 × 10⁵ Da exogenous HA within the range of HA molecular weight synthesised endogenously. After 24, 48, and 72 h of treatment, cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay with Cell proliferation Kit I (Roche Diagnostics).

TUNEL staining

LM8 cells were incubated with or without 1.0 mM MU for 48 h. The cells were fixed with paraformaldehyde and subjected to TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end labelling) stained using an In Situ Cell Death Detection Kit, POD (Roche Diagnostics). Cells with brown-stained nuclei in 10 different fields (200–300 cells per field) were counted under a light microscope at ×400 magnification, and the percentage of positively stained cells was calculated.

Cell-cycle analysis

LM8 cells were incubated with or without 1.0 mM MU for 24 h. The cells were washed with phosphate-buffered saline (PBS), trypsinised, followed by permeabilisation and treatment with RNase, and stained with propidium iodide using a CycleTEST PLUS DNA reagent kit (BD Biosciences). The DNA content of the stained cells was immediately analysed using FACSCalibur (BD Biosciences). The percentages of cells in G0/G1 phase, S phase, and G2/M phase were determined using ModFit LT software (Verity Software House, Topsham, ME, USA).

Motility and matrigel invasion assays

The chemotactic motilities of cells were investigated using 12-well cell culture chambers containing inserts with 12-μm pores (Millipore, Billerica, MA, USA). Invasion of LM8 cells was assayed in the same chambers that contained the inserts with 12-μm pore membrane coated with matrigel. The cells were added to the upper chamber at a density of 5 × 10⁵ cells per insert in the presence or absence of 0.1–1.0 mM MU, and a chemotaxis buffer containing 10 μg ml⁻¹ of fibronectin was added to the lower chamber. After 24 h of incubation, cells on the upper surface were wiped off with a cotton swab. Cells that had invaded the lower surface were fixed with 70% ethanol and stained with haematoxylin. Cells from 10 different fields were counted under a light microscope at ×400 magnification.
In addition, to determine whether the effects of MU are mediated by inhibition of HA synthesis, cell motility and invasiveness with MU were evaluated after knockdown of HA synthases using siRNAs for Has1 and/or Has3. Briefly, siRNAs (MISSION esiRNA; Sigma-Aldrich) for Has1 and/or Has3 were complexed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in Opti-MEM (Invitrogen) according to the manufacturer’s protocol, and then the mixtures were administered to LM8 cells in DMEM with serum and antibiotics. As a control siRNA, GFP siRNA was used. For 48-h incubation, efficiency of knockdown with siRNA for Has1 and/or Has3 was confirmed using real-time RT-PCR. The effects of MU on motility and invasiveness were analysed under the condition of Has1 and/or Has3 knockdown.

Western blot analysis

The effects of MU on the expression levels of Akt and phospho-Akt (p-Akt) protein were assayed by western blot analysis. LM8 cells were incubated with or without 1.0 mM MU for 30 min, and 3, 6, and 12 h, and the cells were lysed on ice in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After centrifugation at 10,000 g for 10 min, the supernatant was subjected to western blot analysis. Protein concentration was determined using the protein assay reagent (Bio-Rad, Philadelphia, PA, USA). The extracted protein (40 μg per lane) was subjected to western blot analysis using rabbit anti-Akt and anti-phospho-Akt (Ser473) polyclonal antibodies (Cell Signaling Technology, Beverly, MA, USA). Species crossreactivity of these polyclonal antibodies with murine Akt and phospho-Akt has been already confirmed by the manufacturer (Cell Signaling Technology).

Effects of MU in vivo

LM8 cells are known to be tumourigenic when injected subcutaneously into syngeneic hosts, and they consistently grow as local tumour masses and develop distant lung metastases (Asai et al, 1998). LM8 cells (2 × 106) suspended in 200 μl of serum-free DMEM were implanted into the dorsal flank of 5-week-old C3H/He male mice and allowed to grow in vivo for a period of 14 days, at which time small tumours (0.8–1.0 cm in diameter) were identified. The mice were randomly divided into two groups (n=8 mice per group). 4-Methylumbelliferone (10 mg per body) with 100 μl of 0.4% CMC solution was intraperitoneally administered daily to mice in the MU group. The same amount of 0.4% CMC solution was administered to the mice in the control group. After 2 weeks of consecutive administration, all the mice were killed, and their local tumours and lungs were excised and analysed for local tumour wet weight and number of metastatic colonies in the lung. All animal experiments were performed in accordance with the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research (Workman et al, 2010) and under approval of the institutional animal ethics committee.

HA staining for cells and tissues

Hyaluronan accumulation in cells and in vivo tissues after incubation with or without MU was observed using hyaluronic acid binding protein (HABP; Seikagaku, Tokyo, Japan). The cells were seeded onto chamber slides (BD Biosciences), allowed to adhere to the bottom of the slides for 12 h, and then incubated with 0–1.0 mM MU with or without exogenous 200 μg ml⁻¹ of HA for 72h. Cultured cells and excised local tumours were subjected to HABP staining. Then, the cells and tissues were incubated with a 2.0 μg ml⁻¹ biotinylated HABP (b-HABP) probe for 2h at room temperature. Bound b-HABP was detected by the addition of streptavidin-peroxidase reagents (Nichirei, Tokyo, Japan) and diaminobenzidine-containing substrate solution (Nichirei).

As previously reported, both extracellular and cytoplasmic HA could be detected with bound b-HABP without permeabilisation for cell staining (Nishida et al, 2005).

Quantification of HA

The subconfluent LM8 cells were incubated with or without 1.0 mM MU for 6, 12, and 24 h. The isolation of HA was based on the methods reported by Tammi et al (2001). Briefly, the conditioned medium was collected and designated as ‘medium’. To remove the cell-surface-associated HA, the cells were incubated for 10 min at 37°C with trypsin-EDTA and washed with PBS. The trypsin solution and combined washes were designated as ‘pericellular’. After cell counts, the cells were placed in Protease K solution (0.15 M Tris-HCl, pH 7.5, 0.15 M NaCl, 10 mM CaCl₂, and 5 mM deferoxamine mesylate containing 20 units of protease K) and incubated for 2 h at 55°C and the solution was designated as ‘intracellular’. All samples were heated at 100°C for 15 min to inactivate protease activity and centrifuged at 15,000 g for 30 min at 4°C, and the supernatants were analysed. The HA concentrations were measured using a sandwich enzyme-linked immunosorbent assay, as described previously (Zhu et al, 2010).

Statistical analysis

All the in vitro quantitative experiments were performed more than 3 times, and analysis of variance followed by Bonferroni–Dunn post-hoc test was used to assess differences between means. Statistical comparisons between the two groups were made using an unpaired Student’s t-test.

RESULTS

MU inhibits HA accumulation in LM8, MG-63, and HOS cells

Cells treated with the control medium for 72 h showed prominent staining for HA. Cells treated with 1.0 mM MU for 72 h showed a substantial inhibition of HA staining (Figure 1A). Cells treated with 1.0 mM MU and 200 μg ml⁻¹ of exogenous HA also showed a faint staining, demonstrating no recovery in HA positivity in any cell line (data not shown). The amount of HA was measured per 10⁶ cells each in LM8 cells. The amount of pericellular HA treated with 1.0 mM MU for 6 h (0.405 ng) was significantly lower than that with control (DMSO) cells (0.514 ng; P < 0.001). The amount of intracellular HA treated with 1.0 mM MU for 6 h (0.137 ng) was also significantly lower than that with control (DMSO) cells (0.195 ng; P < 0.001). In contrast, the amount of HA in medium with MU treatment was not statistically different from that with control treatment. At 12, 24, and 48 h, the amount of HA with MU treatment tended to be lower than that with control treatment, but none of these differences reached statistical significance.

MU inhibits cell-associated matrix formation

One of the functions of HA in tumour cells, particularly mesenchymal tumour cells, as well as other connective tissue cells such as chondrocytes, is to serve as a scaffold for the assembly of a cell-associated matrix (Knudson et al, 1996; Nishida et al, 1999). These matrices may favour independent cell growth, migration, and invasion. Tumour cells in the control medium displayed abundant cell-associated matrices after 72 h of culture (Figure 1B, particularly LM8 and MG-63 cells). However, MU treatment resulted in a substantial decrease in the diameter of cell-associated matrices (Figure 1B). Addition of exogenous HA (200 μg ml⁻¹) could not restore the cell-associated matrix formation in MU-treated LM8 cells (data not shown). Differences in functional cell-associated matrices in LM8 cells were determined by
Figure 1 Effect of MU on HA accumulation in cells and pericellular matrix formation. (A) Histochemical staining of hyaluronic acid binding protein (HABP) in each cell that was either left untreated or incubated with MU (1.0 mM) for 72 h (original magnification × 200). (B) Visualised pericellular matrix that was observed after 72 h of incubation without or with MU (1.0 mM; original magnification × 200). (C) Morphometric analyses were used to determine the proportions of the area delineated by the cell-associated matrix area to the area delineated by the plasma membrane area. Bars represent means ± s.d. from 10 cells of each condition (*P<0.001, compared with DMSO).
morphometric analysis (Figure 1C). The cell-associated matrix area in cells treated with MU was significantly lower than that in the control cells ($P < 0.001$).

**MU alters Has and CD44 expression**

The results of conventional RT-PCR are shown in Figure 2A. The reliability of the primer of Has2 and HAS1 was confirmed by the positive control cells: Has2 for Lewis lung carcinoma cell line, and HAS1 for MDA-MB-231 breast cancer cell line (data not shown). Although a previous study reported that of the three HA synthases, only Has3 was expressed in LM8 cells (Tofuku et al., 2006), both Has1 and Has3 mRNA could be detected. MG-63 cells expressed HAS2 and HAS3, but not HAS1. HOS cells expressed HAS2 and HAS3 mRNA. CD44, which is one of major cell-surface receptors of HA, was detected in each cell line. Results of real-time RT-PCR revealed that the treatment of LM8 cells with 1.0 mM MU for 24 h resulted in significant upregulation of Has1 ($P = 0.016$) (Has3; $P = 0.152$), whereas CD44 mRNA expression was downregulated ($P = 0.01$, Figure 2B). The conventional RT-PCR revealed no marked change in the mRNA expression of HA degradation enzymes, Hyal1, Hyal2, and Hyal3, with or without treatment of 1.0 mM MU for 24 h (Figure 2D).

Results of immunocytochemistry for Has1 and Has3 showed more diffuse positive staining for Has1 in cells treated with MU than that in control cells. In contrast, there seemed to be no difference in Has3 staining between MU-treated cells and control cells (Figure 2C).

**MU inhibits cell proliferation and induces apoptosis**

As shown in Figure 3A, MU inhibited the proliferation of LM8, MG-63, and HOS cells in a dose-dependent manner. The proliferation of each cell treated with 1.0 mM MU for 24 h was lower (25–34% reduction) than that in DMSO ($P < 0.001$ in LM8 and HOS cells and $P = 0.002$ in MG-63 cells). Greater inhibition was observed after treatment with 1.0 mM MU for 48 h (42–53% reduction; $P < 0.001$) and 72 h (62–69% reduction, $P < 0.001$ in each line). However, exogenous HA added concurrently with MU did not cancel the effect of MU in any cell line.

---

**Figure 2**  Effect of MU on hyaluronan and CD44 mRNA expression. (A) Conventional RT-PCR bands of hyaluronan synthase and CD44 transcripts. (B) The relative values of mRNA expression of Has1, Has3, and CD44 in LM8 cells were determined by real-time RT-PCR analysis. The data presented are the average ± s.d. of relative mRNA expression values standardised by GAPDH mRNA expression. Differences between DMSO and MU were significant in Has1 and CD44, but not in Has3 ($^*P < 0.05$, compared with DMSO). (C) Immunocytochemical staining of Has1 and Has3 in LM8 cells that were treated with or without MU (1.0 mM) for 24 h (original magnification × 200). (D) Conventional RT-PCR bands of hyaluronidase in LM8 cells that were either left untreated or incubated with MU (1.0 mM) for 24 h.
In MTT assay, no cytotoxicity of 1% DMSO on cell proliferation was observed as compared with the control cells (without DMSO). To determine the mechanism of the MU-mediated growth inhibition of LM8 cells, the number of apoptotic cells was determined by TUNEL staining. The average percentage of apoptotic cells treated with 1.0 mM MU was higher (1.67-fold) than

\[
\begin{align*}
\text{Absorbance} & \quad 0.0 & \quad 0.2 & \quad 0.4 & \quad 0.6 & \quad 0.8 & \quad 1.0 & \quad 1.2 \\
\text{Incubation period} & \quad 24 \, \text{h} & \quad 48 \, \text{h} & \quad 72 \, \text{h}
\end{align*}
\]

Figure 3  Effect of MU on cell proliferation, apoptotic activity, and cell cycles. (A) MTT assay. The cells were incubated with various concentrations of MU (dissolved in 1% DMSO) for 24, 48, or 72 h. The exogenous HA (\( \sim 8 \times 10^7 \) Da, 200 \( \mu \)g ml\(^{-1} \)) was added concurrently with MU. Bars represent means \( \pm \) s.d. of absorbance readings at 550 nm from experiments performed in triplicate (*\( P < 0.05 \), **\( P < 0.001 \), compared with DMSO; MU 1.0 mM + HA 200 \( \mu \)g ml\(^{-1} \) group was compared with MU 1.0 mM group). (B) TUNEL staining. LM8 cells were cultured with or without MU for 48 h and then assayed by TUNEL staining. The percentage of positive cells with brown-stained nuclei was calculated in 20 different fields by using light microscopy at a magnification of \( \times 200 \). Bars represent means \( \pm \) s.d. (C) The relative values of mRNA expression of Bax and bcl-2 in LM8 cells after treatment with or without MU for 24 h were determined by real-time RT-PCR analysis. The data presented are the average \( \pm \) s.d. of relative mRNA expression values standardised by GAPDH mRNA expression (*\( P < 0.05 \), compared with DMSO). (D) Changes in cell cycles were analysed by using CycleTEST PLUS DNA reagent kit. LM8 cells were incubated with or without 1.0 mM MU for 24 h and then evaluated by flow cytometry. (*\( P < 0.05 \), compared with DMSO at the same stage on cell cycle).
that of the control. However, the difference between the values for control and the 1.0 mM MU treatment groups did not reach statistical significance (Figure 3B, \(P = 0.288\)). Real-time RT-PCR for Bax and bcl-2 also revealed increased apoptotic activity with MU (Bax; \(P = 0.119\), bcl-2; \(P = 0.025\)) expression for 12 h (Figure 3C).

**Effects of MU on cell cycle**

Among the cells treated with 1.0 mM MU for 24 h, the number of cells in the S phase was significantly lower than the corresponding value for the control cells (\(P < 0.05\); Figure 3D), and the number of cells in the G2/M phases in cultures treated with 1.0 mM MU was significantly higher than the corresponding value for the control cells (\(P < 0.05\)).

**MU inhibits cell migration and invasiveness**

At the 24-h time point, the migratory activity of LM8, MG-63, and HOS cells treated with 1.0 mM MU was significantly lower (LM8: 52% reduction, MG-63: 48%, and HOS: 58%) than that of the control cells (\(P < 0.001\), in each cell line, Figure 4A), whereas the migratory activity of cells treated with 0.1 mM MU varied between cell lines (LM8: 10% reduction, \(P = 0.037\); MG-63: 40% reduction, \(P < 0.001\); HOS: 16% reduction, \(P = 0.004\)). In the invasion assay, the capacity of the MU-treated LM8 cells to pass through the Matrigel-coated filters was significantly lower than that of the control cells (Figure 4B). The invasiveness of cells treated with 0.1 and 1.0 mM MU was 57% (\(P < 0.001\)) and 66% (\(P < 0.001\)), respectively, lower than that of the control. Under the condition of Has1 and/or Has3 knockdown with siRNA (efficiency: single knockdown of Has1, 95%; Has3, 92%; double knockdown of Has1 and Has3, 95% and 73%, respectively), the single knockdown of Has1 or Has3 did not compensate for the effects of MU on cell motility or invasiveness, whereas the double knockdown of Has1 and Has3 did (Figure 4C). These results suggested that the inhibitory effects of MU on cell motility and invasiveness are mediated via an HA-dependent route.

**MU inhibits Akt phosphorylation**

A previous report showed the important roles of Akt signalling in the development of pulmonary metastases of osteosarcoma by using LM8 cells (Fukaya et al., 2005). Another study using carcinoma cells showed that perturbation of HA-CD44 binding leads to suppression
of the phosphoinositide 3-kinase (PI3K)/Akt pathway, thereby inhibiting cell and tumour growth (Ghatak et al, 2002). We examined Akt phosphorylation after MU treatment. Western blot analysis showed that Akt phosphorylation in cells treated with MU at 6 and 12 h was lower than that in the control cells, although no difference was observed at 30 min or 3 h (Figure 4D).

MU had inhibitory effects on local tumour growth and lung metastases

Daily administration of MU showed an inhibitory effect on LM8 tumour growth, based on a reduction in tumour wet weight (49% reduction, Figure 5A). However, because of the deviations between values for different tumours, the overall values did not reach significance ($P = 0.251$). The inhibitory effects of MU treatment on local tumour growth may be attributable to decreased HA retention by LM8 cells and/or stromal cells. Analysis of HA by HABP staining revealed that HA retention in MU-treated LM8 local tumours (Figure 5D and F) was lower than that in the control tumours (Figure 5C and E). Interestingly, HA retention was notable in the periphery of control tumours (Figure 5C); however, retention was prominently suppressed by MU treatment (Figure 5D). In addition, HA retention in the surrounding stromal tissues and perivascular lesions with MU treatment was also lower (Figure 5F) than that in the control (Figure 5E). Treatment with MU resulted in a significant (75%) reduction in the number of metastatic lung lesions ($P = 0.009$, Figure 5B). These results can be compared visually. The number of lung metastases in MU-treated mice (Figure 5H) was lower than that in control mice (Figure 5G).

**Figure 5** Effect of MU on implanted tumour mass and lung metastasis of LM8 cells. (A) The wet weights of the transplanted tumour were measured (difference was not significant). (B) The numbers of lung metastases at the coronal midline section. Representative sections of transplanted tumours with HABP staining (C and E; Control, D and F; MU treatment, original magnification $\times 40$). Representative sections of the lung are shown (G, Control; H, MU treatment; original magnification $\times 40$). Bars represent means ± s.d. (*$P<0.05$, compared with control).
In the present study, addition of exogenous HA did not cancel the effect of MU on HA accumulation in cells, formation of cell-associated matrix, or cell proliferation. We speculate that differences in biological potency between exogenous HA (free HA) and endogenous HA (cell-associated HA) may exist.

Although HA-CD44 signalling is known to result in the stimulation of cell motility and proliferation (Kim et al, 2005), the molecular mechanisms of this HA-induced enhanced tumourigenicity remain poorly understood. Recent studies have shown that the PI3K/Akt signalling pathway is significantly involved in HA-induced cell motility and invasiveness. For example, in HA-mediated breast cancer progression, the binding of HA to MD-MB-231 cells induces PI3K/Akt activation, which is effectively blocked by a PI3K inhibitor (Bourguignon et al, 2003; Kim et al, 2005). Exogenous HA oligosaccharides blocked endogenous HA binding to CD44, resulting in the inhibition of PI3K/Akt signalling pathway in murine mammary carcinoma cells (Ghatak et al, 2002). Thus, exogenously administered agents have been well analysed, whereas very few studies have investigated whether MU, which inhibits endogenous HA synthesis, affects the PI3K/Akt pathway. In prostate cancer cells, MU induced downregulation of phosphorylated Akt, indicating that Akt signalling is an important mechanism in the antitumour activity of MU (Lokeshwar et al, 2010). This study, for the first time, demonstrated MU-induced downregulation of Akt phosphorylation in osteosarcoma cells. Considering the delayed inhibition of Akt phosphorylation (after 6 h) by MU in this study, MU may indirectly affect Akt phosphorylation, possibly via suppression of HA synthesis, perturbation of HA-receptor interaction, or alteration of cell signalling pathways including Akt phosphorylation.

The degree of the inhibitory effects of MU on the formation of lung metastasis in vivo was markedly higher than that on the growth of the implanted primary tumour. In contrast to the growth of the primary tumour, multistep processes are associated with distant metastasis. In this study, MU suppressed proliferation, motility, and invasion of osteosarcoma cells in vitro. Inhibition of these steps by MU led to substantial suppression of lung metastasis. Another explanation is that MU affects the microenvironment of the primary and target organs. The tumour stroma and surrounding normal cells (immune cells, inflammatory cells, pericytes, vascular endothelial cells, and fibroblasts) can be affected by MU, possibly via inhibition of HA synthesis. Notably, in the current study, HA deposits were markedly suppressed not only in the periphery of the tumour, but also in the surrounding stromal tissues and perivascular region in vivo. In the clinical context, the strong suppressive effects of MU on lung metastasis might be especially beneficial for patients with osteosarcoma, considering that the primary cause of death in this group is lung metastasis (Ta et al, 2009).

Several studies have shown suppression of tumourigenicity by using genetic modification of HA synthases or the administration of HA oligos (Simpson et al, 2002; Nishida et al, 2005; Hosono et al, 2007). However, genetic modification has limited clinical applicability because of the predicted complications and ethical issues, and the administration of HA oligos is impractical for clinical use or drug delivery. In contrast, as MU has already been clinically used as an oral choleretic agent in Japan, it can be readily used for osteosarcoma patients. However, the optimal dose to attain anticancer effects needs to be established. In the United States, the oral administration of MU at 2.2 g day⁻¹ has been used in trials for the treatment of hepatitis B and C (ClinicalTrials.gov, number, NCT00225537). The complications and dose-limiting toxicity of MU treatment will be clarified after clinical trials.

In conclusion, we showed that MU inhibited various processes of tumourigenicity in vitro in murine and human osteosarcoma cell lines, and markedly suppressed lung metastasis in highly metastatic murine osteosarcoma cells. Although clinical trials are required to clarify the efficacy of MU in human patients.
with osteosarcoma, the results of this study suggest that MU might be a novel antimetastasis agent for the treatment of osteosarcoma.

ACKNOWLEDGEMENTS

We thank Eri Ishihara for secretarial assistance and Daizo Kato for technical advises for the experiments. This study was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid 20591751 for Scientific Research (C); to Y Nishida).

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES

Antilla MA, Tammi RH, Tammi MI, Syrjanen KI, Saarikoski SV, Kosma VM (2000) High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60: 150 – 155

Asai T, Ueda T, Itou K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H (1998) Establishment and characterization of a murine osteosarcoma cell line (LMS) with high metastatic potential to the lung. Int J Cancer 76: 418 – 422

Auvinen T, Tammi R, Parkkinnen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156: 529 – 536

Bharadwaj AG, Konwar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA (2000) Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 147: 1027 – 1036

Bourguignon LY, Singleton PA, Zhu H, Diederich F (2003) Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated-binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278: 29240 – 29247

Fukaya Y, Ishiguro N, Senga T, Ichigotani Y, Sohara Y, Tsutsui M, Shioura T, Iwamoto T, Hamaguchi M (2005) A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LMS. Oncol Rep 14: 847 – 852

Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277: 38013 – 38020

Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki T, Ishiguro N (2007) Hyaluronan oligosaccharides inhibit tumorigenicity and anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt pathway. J Biol Chem 272: 38013 – 38020

Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, Shinomura T, Hamaguchi M, Yoshida Y, Ohsuki Y, Miyauchi S, Spicer AP, McDonald JA, Kimata N (1999) Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 274: 25085 – 25092

Kakizaki I, Kojima K, Takagaki K, Endo M, Kannagi R, Ito M, Maruo Y, Sato H, Yasuda T, Mita S, Kimata K, Itano N (2004) A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliflere. J Biol Chem 279: 33281 – 33289

Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES, Lee SH (2005) Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human gastric cancer cells. Cancer Res 65: 686 – 691

Knudson CB (1993) Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix. J Cell Biol 120: 825 – 834

Knudson CB, Biswas C, Li XQ, Nemec RE, Toole BP (1989) The role and regulation of tumour-associated hyaluronan. Ciba Found Symp 143: 150 – 169

Knudson W, Aguilar DJ, Hu Q, Knudson CB (1996) CD44-anchored hyaluronan-rich pericellular matrices: an ultrastructural and biochemical analysis. Exp Cell Res 228: 216 – 222

Kudo D, Kon A, Yoshihara S, Kakizaki I, Sasaki M, Endo M, Takagaki K (2004) Effect of a hyaluronan synthase suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell adhesion and locomotion. Biochem Biophys Res Commun 321: 783 – 787

Kultti A, Pasonen Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E, Tammi RH, Tammi MI (2009) 4-Methylumbelliflere inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315: 1914 – 1923

Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N (2010) Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliflere in prostate cancer cells. Cancer Res 70: 2613 – 2623

McBride WH, Bard JB (1979) Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytosis. J Exp Med 150: 507 – 515

Munn K, Maas Kuck K, Schumacher U, Schulz T, Hallmann R, Schnaker EM, Schneider SW, Prehm P (2008) Inhibition of hyaluronan export attenuates cell migration and metastasis of human melanoma. J Cell Biochem 105: 1260 – 1266

Mummert ME, Mummert DL, Ellinger L, Takashima A (2003) Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice. Mol Cancer Ther 2: 295 – 300

Nakazawa H, Yoshihara S, Kudo D, Morohashi H, Kakizaki I, Kon A, Takagaki K, Sasaki M (2006) 4-methylumbelliflere, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol 57: 165 – 170

Nishida Y, Knudson CB, Nietfeld JJ, Margulis A, Knudson W (1999) Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly. J Biol Chem 274: 21893 – 21899

Nishida Y, Knudson W, Knudson CB, Ishiguro N (2005) Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cell lines promotes tumor cell invasion and angiogenesis. Am J Pathol 166: 247 – 263

Pirinen RT, Tammi RH, Tammi MI, Paakkko PK, Parkkinnen J, Agren UM, Johansson RT, Viren MM, Tormanen U, Soini YM, Kosma VM (1998) Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung. Int J Cancer 79: 251 – 255

Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwivat S, Byers S, Marshall VR, Tillely WD, Horsfall DJ (2007) Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 282: 10814 – 10825

Rilla K, Pasonen Seppanen S, Rieppo I, Tammi M, Tammi R (2004) The hyaluronan synthase inhibitor 4-methylumbelliflere prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol 123: 708 – 714

Ropponen K, Tammi M, Parkkinnen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E, Kosma VM (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342 – 347

Setala LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Agren UM, Parkkinnen J, Alhava EM, Kosma VM (1999) Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 79: 1133 – 1138

Simpson MA, Wilson CM, McCarth JY (2002) Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 161: 849 – 857

Suzuki Y, Nishida Y, Naruse T, Gembta T, Ishiguro N (2009) Pericellular matrix formation alters the efficiency of intracellular uptake of oligonucleotides in osteosarcoma cells. J Surg Res 152: 148 – 156

Takeda S, Aburada M (1981) The choletheretic mechanism of coumarin compounds and phenolic compounds. J Pharmacobiodyn 4: 724 – 734
Tammi R, Rilla K, Pienimaki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M (2001) Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem 276: 35111 – 35122
Tofuku K, Yokouchi M, Murayama T, Minami S, Komiya S (2006) HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells. Int J Oncol 29: 175 – 185
Tominaga A, Tajima S, Ishibashi A, Kimata K (2001) Reticular erythematous mucinosis syndrome with an infiltration of factor XIIIa+ and hyaluronan synthase 2+ dermal dendrocytes. Br J Dermatol 145: 141 – 145
Toole BP (2009) Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 15: 7462 – 7468
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham D, GlennieMJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA, An ad hoc committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555 – 1577
Yang B, Zhang L, Turley EA (1993) Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J Biol Chem 268: 8617 – 8623
Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M, Endo M, Takagaki K (2005) A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 579: 2722 – 2726
Zhu L, Zhuo LS, Kimata K, Yamaguchi E, Watanabe H, Aronica MA, Hascall VC, Baba K (2010) Deficiency in the serum-derived hyaluronan-associated protein-hyaluronan complex enhances airway hyperresponsiveness in a murine model of asthma. Int Arch Allergy Immunol 153: 223 – 233

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.